Donor pretreatment with ProGP-1 attenuates GVHD severity.
Survival curves by Kaplan-Meier analysis, pooled from 2 similar experiments. Donor B6 mice were treated with G-CSF (10 μg/animal per day for 10 days), ProGP-1 (20 μg/animal per day for 10 days), or control diluent. Splenocytes (107) from control– (•, control allogeneic, n = 15), G-CSF– (▴, G-CSF allogeneic, n = 20), and ProGP-1–treated (□, ProGP-1 allogeneic, n = 15) donors were harvested on day 11 and transplanted into lethally irradiated (1100 cGy) B6D2F1 recipient mice. Additional ProGP-1 T cells were added to a ProGP-1 (■, ProGP-1 allogeneic adjusted, n = 13) cohort to equilibrate the T-cell dose across the groups. Control-treated T-cell–depleted (○, TCD allogeneic, n = 8) spleens were transplanted as non-GVHD controls. Survival,P < .0001 for control allogeneic versus all others,P = .05 for G-CSF allogeneic versus ProGP-1 allogeneic.
